Floatz Rating
B56/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03464305CT.gov ASPIRIN Trial Belgium | — | Active Not Recruiting | — | — | — |
NCT03047837CT.gov A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients | — | Terminated | — | — | — |
NCT02301286CT.gov A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT00468910CT.gov Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colon Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aspirin (this asset) | M.D. Anderson Cancer Center | P3 | B · 56 |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Fluorouracilum | Akeso | P4 | BB |
| Pertuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Trastuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Palbociclib | Lebanese University | P2 | BB |
| Encorafenib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | BB |
+42 more in the Colon Carcinoma cohort
Other indications for Aspirin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | A · 83 |
| Coronary Artery Disorder | — | P4 | BBB · 79 |
| Cardiovascular Disorder | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aspirin in Colon Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aspirin-colon-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →